Skip to content
IBOImpact Biomedical Inc.

Earnings

When Impact Biomedical Inc. reports, what it reported each quarter, and how the stock took the results.

18 quarters. Jun 30, 2022 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

10-K due Feb 16 – Apr 2

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 3 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 16 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q3 2026 +16.7%, Q2 2026 −57.1%, Q1 2026 n/m, Q3 2025 n/m
Net income
$5.25M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$21.00K+16.7% vs Q3 2025

Latest results

  1. Q3 2026Nov 9, 2026, after the close+7.7%by the close of Nov 10
    Revenue
    $21.00K
    +16.7%
    Net income
    -$645.00K
    N/M
    EPS
    -$0.08
    N/M
  2. Q2 2026Aug 7, 2026, after the close4.4%by the close of Aug 11
    Revenue
    $3.00K
    −57.1%
    Net income
    -$699.00K
    N/M
    EPS
    -$0.01
    N/M
  3. Q1 2026May 12, 2026, after the close7.9%by the close of May 13
    Revenue
    $7.00K
    —
    Net income
    -$2.29M
    N/M
    EPS
    -$0.02
    N/M
  4. Q4 2025Mar 11, 2026, after the close1.8%by the close of Mar 12
    Revenue
    —
    —
    Net income
    $5.25M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026—Nov 9, 202640 d10-Q$21.00K+16.7%-$0.08+7.7%
Q2 2026Jun 30, 2026—Aug 7, 202638 d10-Q$3.00K−57.1%-$0.014.4%
Q1 2026Mar 31, 2026—May 12, 202642 d10-Q$7.00K—-$0.027.9%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 11, 202670 d10-K———1.8%
Q3 2025Sep 30, 2025—Nov 7, 202538 d10-Q$18.00K—-$1.52+1.8%
Q2 2025Jun 30, 2025—Aug 14, 202545 d10-Q$7.00K—-$1.18+4.7%
Q1 2025Mar 31, 2025—May 14, 202544 d10-Q——-$0.11+2.0%
FY 2024
Q4 2024derivedDec 31, 2024—Mar 28, 202587 d10-K———42.8%
Q3 2024Sep 30, 2024—Nov 12, 202443 d10-Q——$0.061.1%
Q2 2024Jun 30, 2024—Aug 13, 202444 d10-Q——-$0.09—
Q1 2024Mar 31, 2024—May 10, 202440 d10-Q——-$0.10—
Earlier years, FY 2022 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026050750
10-QAug 7, 2026036601
10-QMay 12, 2026022512
10-KMar 11, 2026009711
10-QNov 7, 2025021286
10-QAug 14, 2025023809
10-QMay 14, 2025010276
10-KMar 28, 2025001199
10-QNov 12, 2024044792
10-QAug 13, 2024031635

Provenance

ProvenanceData status and checks

Impact Biomedical Inc. · CIK 1834105 · Engraved from SEC EDGAR